Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided:	n/a
For commercial reagents, provide supplier name, catalogue number and RRID, if available.		The article does not cover antibodies

Cell materials	Yes (indicate where provided:	n/a
Cell lines: Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		The article does not cover cell lines
Primary cultures: Provide species, strain, sex of origin, genetic modification status.		The article does not cover cell materials

Experimental animals	Yes (indicate where provided:	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID		The article does not cover experimental animals
Animal observed in or captured from the field: Provide species, sex and age where possible		The article does not cover experimental animals
Model organisms: Provide Accession number in repository (where relevant) **OR** RRID		The article does not cover experimental

Plants and microbes	Yes (indicate where provided:	n/a
Plants: provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		The article does not cover plants
Microbes: provide species and strain, unique accession number if available, and source		The article does not cover microbes

Human research participants	Yes (indicate where provided:	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		The study did not involve human research participants
Provide statement confirming informed consent obtained from study participants.		The study did not involve human
Report on age and sex for all study participants.		The study did not

Design

Study protocol	Yes (indicate where provided:	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.	Page 2,line 22-33, Abstract	

Laboratory protocol	Yes (indicate where provided:	n/a
Provide DOI or other citation details if detailed step-by-step protocols are available.		the study did not cover detailed step-

Experimental study design (statistics details)	Yes (indicate where provided:	n/a
State whether and how the following have been done**, or** if they were not carried out.	Page 5,line 89-104, Data processing	
Sample size determination	Materials and Methods	
Randomisation	Page 5-6,line 107-113	
Blinding	Page 6,line 116-124	
Inclusion/exclusion criteria	Page 6,line 127-130	

Sample definition and in-laboratory replication	Yes (indicate where provided:	n/a
State number of times the experiment was replicated in laboratory		the study did not involve
Define whether data describe technical or biological replicates	Page 4,line 73-86	

Ethics	Yes (indicate where provided:	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		the study did not involve
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		the study did not involve
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		the study did not involve

Dual Use Research of Concern (DURC)	Yes (indicate where provided:	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval		the study did not involve

Analysis

Attrition	Yes (indicate where provided:	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.		the study did not involve

Statistics	Yes (indicate where provided:	n/a
Describe statistical tests used and justify choice of tests.	Page 12-13,line 253-268	

Data Availability	Yes (indicate where provided:	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.		the study did not involve
If data are publicly available, provide accession number in repository or DOI or URL.	Page 4,line 73	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	Page 4,line 73	

Code Availability	Yes (indicate where provided:	n/a
For all newly generated code and software essential for replicating the main findings of the study:		the study did not involve
State whether the code or software is available.	Materials and Methods,paragraph 1	
If code is publicly available, provide accession number in repository, or DOI or URL.	Materials and Methods,paragraph 1	

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.		the study did not involve
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	the study did not involve

Article Information: http://dx.doi.org/10.21037/tau-19-911